PR NEWS Logo
Home
PR NewsWire
NewsWire Today
MarketWire
Submit Your Feeds
Business News
•
MarketWire
• Vernalis and Servier Achieve Research Milestone as BCL-2 Inhibitor Drug Candidate Enters Phase I
Vernalis and Servier Achieve Research Milestone as BCL-2 Inhibitor Drug Candidate Enters Phase I
Vernalis and Servier Achieve Research Milestone as BCL-2 Inhibitor Drug Candidate Enters Phase I
WINNERSH, UNITED KINGDOM--(Marketwired - Jun 19, 2014) - Vernalis PLC (LSE: VER) (PINKSHEETS: VNLPY)
View More :
http://www.marketwired.com/mw/release.do?id=1922227&sourceType=3
Releted News by marketwire
Ã"gypten wird bei bevorstehender Neuordnung der Russell-Indizes als Frontier-Markt eingestuft
Vernalis and Servier Achieve Research Milestone as BCL-2 Inhibitor Drug Candidate Enters Phase I